Letter of Intent Template & Negotiation Guide for Veterinary Specialty Practice Acquisitions

Parties and Practice Identification

Identifies the buyer entity, the seller (typically the practice owner or ownership group), and the target practice by legal name, DBA, and physical location. For specialty practices with multiple locations or a parent holding entity, all entities with DEA registrations, state veterinary board licenses, and equipment ownership must be listed explicitly.

💡 Sellers with multiple specialists operating under separate professional corporations or with equipment held in a separate LLC should flag this early. Buyers need to understand the full entity map before the LOI is signed, as DEA registrations are not transferable and new registrations must be obtained by the acquiring entity — a process that can take 60–90 days and affect the closing timeline.

Transaction Structure

Defines whether the deal is structured as an asset purchase or stock/equity purchase, and outlines which assets and liabilities transfer to the buyer. Most specialty practice acquisitions in the lower middle market are structured as asset purchases to give buyers a stepped-up tax basis and to avoid assuming undisclosed liabilities, including historical DEA compliance issues.

💡 PE-backed consolidators frequently prefer stock purchases for tax and operational simplicity when acquiring entities with established Medicare/Medicaid-equivalent payor contracts, but most lower middle market specialty vet deals use asset purchases. If the practice has a long-term facility lease with favorable terms, buyers should confirm assignability with the landlord prior to LOI signing or include a contingency. DEA asset transfer protocols must be addressed explicitly — this is non-negotiable and often overlooked in generic LOI templates.

Purchase Price and Valuation Basis

States the proposed total enterprise value, the methodology used to arrive at that figure (typically a multiple of trailing twelve-month or last full-year EBITDA), and the allocation between tangible asset value and goodwill. Specialty practices typically trade at 4.5x–7.5x EBITDA, with higher multiples awarded to practices with multiple board-certified specialists, diversified referral bases, and owned real estate.

💡 Specialty practice valuations are highly sensitive to EBITDA add-backs — sellers frequently add back owner compensation above market, personal vehicle expenses, and non-recurring costs. Buyers should require a formal quality of earnings analysis before committing to a final multiple. If a single specialist generates more than 50% of revenue, buyers should push for a lower base multiple with an earnout mechanism tied to that specialist's continued production. Sellers should push back on goodwill allocation being too high relative to tangible assets, as goodwill is taxed as ordinary income for asset purchase sellers.

Deal Structure and Financing

Outlines how the purchase price will be funded, including SBA 7(a) loan proceeds, buyer equity injection, seller note, and any earnout component. This section also addresses the seller's equity rollover if they are staying on as a minority partner or clinical director, which is common when the selling specialist is a key driver of referral volume.

💡 SBA 7(a) financing is widely available for specialty veterinary practice acquisitions, but lenders will scrutinize specialist employment contracts, referral concentration, and equipment condition. Sellers should understand that a seller note is typically required by SBA lenders and represents deferred risk to the seller. Earnouts tied to specialist retention are seller-friendly in that they motivate the buyer to retain the specialist but can become contentious if the buyer changes management practices that affect specialist satisfaction. Define earnout metrics clearly and avoid EBITDA earnouts that can be manipulated by post-close expense decisions.

Earnout Terms and Specialist Retention Provisions

Provides specific mechanics for any earnout component, including the performance metrics, measurement periods, payment timing, and conditions that trigger or reduce earnout payments. In specialty veterinary deals, earnouts are almost always tied to some combination of revenue, EBITDA, and the continued employment of key board-certified specialists.

💡 Sellers who are the key specialist should negotiate a floor earnout payment that is not contingent on their own continued employment — otherwise, a buyer could constructively terminate the specialist to avoid the earnout. Include anti-sandbagging language requiring the buyer to take commercially reasonable steps to retain referred cases and maintain referral relationships. Buyers should require that the seller not solicit referred practices or specialist staff during the earnout period, mirroring the non-compete terms.

Due Diligence Period and Access

Defines the length and scope of the buyer's due diligence investigation, the seller's obligations to provide access to records, facilities, and personnel, and any carve-outs for sensitive information (e.g., individual patient records, DEA controlled substance logs) that require additional handling protocols.

💡 Forty-five days is standard for specialty practices given the complexity of equipment appraisals and DEA compliance review. Buyers using SBA financing may need up to 60 days to satisfy lender due diligence requirements simultaneously. Sellers should resist allowing buyers to contact referring veterinarians directly during due diligence — this creates market disruption risk. Instead, agree on a structured process where the seller introduces the buyer to top referring practices late in due diligence under a controlled narrative.

Exclusivity and No-Shop Provision

Grants the buyer an exclusive negotiating period during which the seller agrees not to solicit, entertain, or accept competing offers for the sale of the practice. This protects the buyer's investment of time and money in due diligence and deal structuring.

💡 Sixty-day exclusivity periods are appropriate for specialty vet deals given SBA processing timelines. Sellers should resist exclusivity periods longer than 75 days without a clear closing milestone requirement on the buyer. If the buyer fails to deliver a definitive purchase agreement within the exclusivity period, the no-shop provision should automatically terminate. Sellers currently being courted by PE-backed consolidators should understand that exclusivity forecloses competing bids — use the period strategically to negotiate favorable terms before signing.

Conditions to Closing

Lists the material conditions that must be satisfied before the transaction closes, including financing approval, regulatory transfers, specialist contract assignments, lease assignments, and satisfactory resolution of any due diligence findings. These conditions protect both parties from being obligated to close on a deal that has materially changed.

💡 Buyers should insist on individual employment agreement execution as a hard closing condition — not just a best-efforts obligation. If a key specialist refuses to sign a new employment agreement post-LOI, the buyer needs the right to walk away without penalty. Sellers should negotiate for a 'material adverse change' definition that excludes industry-wide events (e.g., broad disruptions to pet insurance reimbursements or veterinary labor market conditions) to prevent a buyer from using a narrow MAC claim to exit a deal opportunistically.

Non-Compete and Non-Solicitation

Establishes the geographic scope, duration, and prohibited activities under the seller's non-compete agreement. For selling board-certified specialists, this section is particularly sensitive — buyers need protection against the seller opening or joining a competing specialty practice, while sellers must preserve their ability to continue practicing their specialty in some capacity.

💡 Non-compete enforceability for licensed professionals varies significantly by state — California, Minnesota, and North Dakota have near-total prohibitions on non-competes, which can significantly reduce a buyer's protection and affect valuation. Buyers in restrictive states should rely more heavily on earnout structures and non-solicitation of referral sources rather than practice restrictions. The geographic radius should reflect the realistic catchment area for the specialty — neurology and oncology practices often draw from a 50-mile radius, while emergency practices may have a tighter 15-mile zone. Sellers should ensure the non-compete does not restrict teaching, research, or specialist board activities.

Confidentiality

Requires both parties to keep the terms of the LOI, the existence of negotiations, and all information shared during due diligence strictly confidential. For specialty practices, confidentiality is especially critical to prevent disruption to referring veterinarians, specialist staff, and clients who may react negatively to premature disclosure of a sale.

💡 In specialty veterinary acquisitions, premature disclosure to referring general practices is one of the most common causes of referral volume disruption and deal failure. Sellers should insist on a joint communication plan — agreed upon before any outreach to referring practices — that positions the acquisition positively. Buyers who leak deal news to competitors or referring practices during due diligence should face liquidated damages provisions. Consider executing a standalone NDA before sharing financial statements, even prior to the formal LOI.

Transition and Post-Closing Obligations

Outlines the seller's obligations to support a smooth operational transition after closing, including introductions to referring veterinarians, training of the buyer or new management on clinical workflows, and any agreed-upon post-closing employment or consulting arrangement for the selling specialist.

💡 Transition support is one of the most undervalued components of a specialty veterinary deal. Referral relationships are personal — referring GPs want to hear directly from the selling specialist that the practice is in good hands before they continue sending cases. Buyers should negotiate a minimum of 90 days of seller clinical presence post-close. Sellers who want a clean exit should negotiate a firm end date with no open-ended consulting obligations. If the seller is staying on as a minority equity holder post-close, this section should reference the separate operating agreement governing that arrangement.